Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

被引：112
|
作者：
Cavo, M [1 ]
Zamagni, E [1 ]
Cellini, C [1 ]
Tosi, P [1 ]
Cangini, D [1 ]
Cini, M [1 ]
Valdrè, L [1 ]
Palareti, G [1 ]
Masini, L [1 ]
Tura, S [1 ]
Baccarani, M [1 ]
机构：
[1] Inst Hematol & Med Oncol Seragnoli, I-40138 Bologna, Italy
来源：
BLOOD | 2002年 / 100卷 / 06期
关键词：
D O I：
10.1182/blood-2002-06-1674
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2272 / 2273
页数：2
相关论文
共 50 条
  • [1] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    Zangari, M
    Anaissie, E
    Barlogie, B
    Badros, A
    Desikan, R
    Gopal, AV
    Morris, C
    Toor, A
    Siegel, E
    Fink, L
    Tricot, G
    BLOOD, 2001, 98 (05) : 1614 - 1615
  • [2] Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy
    Jeng, Wen-Juei
    Kuo, Ming-Chung
    Shih, Lee-Yung
    Chu, Pao-Hsien
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 87 (05) : 542 - 544
  • [3] Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma
    Wang, M
    Weber, DM
    Delasalle, K
    Alexanian, R
    AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (03) : 194 - 197
  • [4] First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation, in young patients (<61 years) with symptomatic multiple myeloma
    Abdelkefi, A
    Ben Romdhane, N
    Omri, H
    Elloumi, M
    Bellaj, H
    Ben othman, T
    Ladeb, S
    Torjman, L
    Lakhal, A
    Jeddi, R
    Aissaoui, L
    Saad, A
    Hsairi, M
    Boukef, K
    Dellagi, K
    Ben abdeladhim, A
    BONE MARROW TRANSPLANTATION, 2005, 35 : S250 - S250
  • [5] Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma.
    Thomas, Sheeba K.
    Giralt, Sergio A.
    Wang, Michael
    Delasalle, Kay B.
    Gavino, Maria
    Rankin, Kim
    Alexanian, Raymond
    Weber, Donna M.
    BLOOD, 2006, 108 (11) : 1019A - 1019A
  • [6] Superiority of the thalidomide-dexamethasone combination on the VAD in the first line before autograft in the multiple myeloma
    Moreau, Anne-Sophie
    HEMATOLOGIE, 2005, 11 (05): : 303 - 304
  • [7] Response: Lenalidomide therapy and deep-vein thrombosis in multiple myeloma
    Rajkumar, SV
    Gertz, MA
    BLOOD, 2006, 108 (01) : 404 - 404
  • [8] Bortezomib thalidomide dexamethasone as first-line treatment in Newly Multiple Myeloma Patients in Peru
    Vasquez, Jule
    Castillo, Claudia
    Lopez, Naty
    Quintana, Shirley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S248 - S248
  • [9] Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation
    Garderet, L.
    Iacobelli, S.
    Moreau, P.
    Dib, M.
    Caillot, D.
    Niederwieser, D.
    Masszi, T.
    Fontan, J.
    Michallet, M.
    Gratwohl, A.
    Milone, G.
    Doyen, C.
    Pegourie, B.
    Hajek, R.
    Casassus, P.
    Kolb, B.
    Chaleteix, C.
    Hertenstein, B.
    Onida, F.
    Ludwig, H.
    Vekemans, M. C.
    Ketterer, N.
    Daguenel, A.
    Koenecke, C.
    Gorin, N. -C.
    Harousseau, J. -L.
    de Witte, T.
    Morris, C.
    Gahrton, G.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S3 - S3
  • [10] First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
    Tosi, P
    Zamagni, E
    Cellini, C
    Parente, R
    Cangini, D
    Tacchetti, P
    Perrone, G
    Ceccolini, M
    Boni, P
    Tura, S
    Baccarani, M
    Cavo, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (05) : 399 - 404
12345